A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis

Nature Clinical Practice Rheumatology

Volumn 2, Issue 10, 2006, Pages 546-553

  Boonen, Annelies ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT;

ABSENTEEISM; ANKYLOSING SPONDYLITIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; EMPLOYMENT; HEALTH CARE COST; HOSPITALIZATION; HUMAN; JOB PERFORMANCE; JOB SATISFACTION; KINESIOTHERAPY; MEDICAL LEAVE; PHYSIOTHERAPY; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SEX DIFFERENCE; SPA TREATMENT; WORK CAPACITY; WORK DISABILITY; WORKING TIME;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; EMPLOYMENT; FEMALE; HUMANS; MALE; SPONDYLITIS, ANKYLOSING;

EID: 33749354106     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0297     Document Type: Review

References (36)

1. van der Linden SM et al. (1984) The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 27: 241-249
2. Braun J et al. (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41: 58-67
3. Akkoc N and Khan MA (2005) Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: Comment on the article by Braun et al. Arthritis Rheum 52: 4048-4049
4. Stucki G et al. (2002) Application of the International Classification of Functioning, Disability and Health (ICF) in clinical practice. Disabil Rehabil 24: 281-282
5. World Health Organisation (2001) International Classification of Functioning, Disability and Health. Geneva: WHO
6. Braun J et al. (2002) Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359: 1187-1193
7. Brandt J et al. (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48: 1667-1675
8. Davis JC Jr et al. (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 48: 3230-3236
9. Gorman JD et al. (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. NEJM 346: 1349-1356
10. Calin A et al. (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63: 1594-1600
11. van der Heijde D et al. (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52: 582-591
12. Boonen A et al. (2001) Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. J Rheumatol 28: 1056-1062
13. Gran JT and Husby G (1984) Ankylosing spondylitis: A comparative study of patients in an epidemiological survey, and those admitted to a department of rheumatology. J Rheumatol 11: 788-793
14. Lehtinen K (1983) 76 patients with ankylosing spondylitis seen after 30 years of disease. Scand J Rheumatol 12: 5-11
15. Guillemin F et al. (1990) Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors. Arthritis Rheum 33: 1001-1006
16. Boonen A et al. (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: A cross sectional study of Dutch patients. Ann Rheum Dis 60: 353-358
17. Boonen A et al. (2001) Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 60: 1033-1039
18. Boonen A et al. (2002) Work status and productivity costs due to ankylosing spondylitis: Comparison of three European countries. Ann Rheum Dis 61: 429-437
19. Barlow JH et al. (2001) Work disability among patients with ankylosing spondylitis. Arthritis Care Res 45: 424-429
20. Mau W et al. (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32: 721-728
21. Zink A et al. (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis. Results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27: 613-622
22. Ward M and Kuzis S (2001) Risk Factors for Work disability in Patients with Ankylosing Spndylitis. J Rheumatol 28: 315-321
23. Wordsworth BP and Mowat AG (1986) A review of 100 patients with ankylosing spondylitis with particular reference to socio-economic effects. Br J Rheumatol 25: 175-180
24. Kobelt G et al. (2004) The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade(R)). Rheumatology (Oxford) 43: 1158-1166
25. Kobelt G et al. (2006) Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 33: 289-295
26. Boonen A et al. (2003) Direct costs of ankylosing spondylitis and its determinants: An analysis among three European countries. Ann Rheum Dis 62: 732-740
27. Boonen A et al. (2005) Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis 64: 396-402
28. Ward MM (2002) Functional disability predicts total costs in patients with ankylosing spondylitis. Arthr Rheum 46: 223-231
29. Boonen A and van der Heijde D (2005) Review of the cost of illness of ankylosing spondylitis and methodological notes. Expert Rev Pharmacoeconomics Outcomes Res 5: 163-181
30. Van Tubergen A et al. (2002) Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial. Arthritis Rheum 47: 459-467
31. Kobelt G et al. (2006) The cost-effectiveness of infliximab (Remicade®) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 33: 732-740
32. Boonen A et al. (2006) Markov model into the cost-utility of etanercept and infliximab in patients with active ankylosing spondylitis. Annals Rheum Dis 65: 201-208
33. Calin A et al. (1994) A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21: 2281-2285
34. Garrett S et al. (1994) A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21: 2286-2291
35. EuroQol Group (1990) EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 16: 199-208
36. van Echteld I et al. Identification of the most common problems by patients with ankylosing spondylitis using the International Classification of Functioning, Disability and Health. J Rheumatol, in press